geraniol has been researched along with Liver Failure, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y; Ma, J; Xu, Y; Zhang, M | 1 |
| Jiang, Y; Li, Y; Wang, N | 1 |
2 other study(ies) available for geraniol and Liver Failure, Acute
| Article | Year |
|---|---|
Geraniol ameliorates acute liver failure induced by lipopolysaccharide/D-galactosamine via regulating macrophage polarization and NLRP3 inflammasome activation by PPAR-γ methylation Geraniol alleviates acute liver failure.
Topics: Acyclic Monoterpenes; Animals; Cytokines; Galactosamine; Inflammasomes; Lipopolysaccharides; Liver Failure, Acute; Macrophages; Methylation; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; PPAR gamma; Signal Transduction | 2023 |
Geraniol protects against lipopolysaccharide and D-galactosamine-induced fulminant hepatic failure by activating PPARγ.
Topics: Acyclic Monoterpenes; Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Galactosamine; Interleukin-1beta; Lipopolysaccharides; Liver; Liver Failure, Acute; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Oils, Volatile; Plant Oils; PPAR gamma; Protective Agents; Signal Transduction; Terpenes; Tumor Necrosis Factor-alpha | 2019 |